Mesenchymal stromal cells for systemic sclerosis treatment

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Systemic sclerosis (SSc) is a rare, chronic autoimmune disease with high morbidity and mortality.
• Key pathological features include vasculopathy, immune dysregulation, and progressive fibrosis.
• Current treatments for SSc are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review the current knowledge on mesenchymal stromal cells (MSC) for SSc treatment.
• To summarize MSC properties, preclinical findings, and clinical trial results in SSc.

Main Methods:

• Review of literature on MSC definition, properties, and functions.
• Analysis of preclinical studies in SSc animal models.
• Evaluation of early clinical trials and ongoing studies in human SSc patients.

Main Results:

• MSC possess pro-angiogenic, immunosuppressive, and anti-fibrotic properties.
• Preclinical studies demonstrated reduced skin and lung fibrosis after MSC infusion in SSc models.
• Early clinical trials indicate a favorable safety profile and potential efficacy in SSc patients.

Conclusions:

• Mesenchymal stromal cells represent a promising therapeutic approach for SSc.
• MSC therapy targets key pathological mechanisms of SSc, including fibrosis and immune dysregulation.
• Further clinical trials are warranted to establish the efficacy and optimal use of MSC in SSc management.